Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 7/20 | 0.81 |
| ▸ | IKBKB | O14920 | 2/20 | 0.81 |
| ▸ | CHUK | O15111 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | INSR | P06213 | 2/20 | 0.81 |
| ▸ | CDK2 | P24941 | 2/20 | 0.81 |
| ▸ | FLT3 | P36888 | 2/20 | 0.81 |
| ▸ | TNIK | Q9UKE5 | 14/20 | 0.67 |
| ▸ | SGK1 | O00141 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 1/20 | 0.67 |
| ▸ | MET | P08581 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12965684 | 0.90 | INSR (0.64) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL15758725 | 0.90 | MAP3K11 (0.83) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL20634223 | 0.90 | MAP3K11 (0.67) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL12067524 | 0.90 | MAP3K11 (1.00) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL31352939 | 0.87 | TNIK (0.80) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL31089792 | 0.85 | TNIK (0.86) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL12067580 | 0.84 | TNIK (0.72) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL721023 | 0.82 | MAP3K11 (0.93) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL15154822 | 0.81 | MAP3K11 (0.84) | MAP3K11IKBKBCHUKABL1INSR | |
| SCHEMBL723009 | 0.81 | MAP3K11 (0.83) | MAP3K11ABL1INSRCDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | MAP3K11 25/4885IKBKB 285/4885CHUK 96/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | MAP3K11 45/4885IKBKB 487/4885CHUK 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.